Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors.
A series of ligands that allosterically modulate the binding of classical ligands to muscarinic receptors was evaluated at wild-type and chimeric receptors. All of the ligands studied had highest affinity toward the M(2) subtype and lowest affinity toward the M(5) subtype. The chimeric receptors were mostly M(5) sequence; the amount of M(2) sequence ranged from about 6 to just under 30%. Alcuronium and TMB-8 had much higher affinity for the chimeric receptor that included the M(2) second outer loop of the receptor plus flanking regions of TM4 and TM5 than for any of the other chimeric receptors (the affinities of which remained similar to that of the M(5) subtype). However, this chimera retained the negative cooperativity between alcuronium and the classical antagonist N-methylscopolamine that is characteristic of M(5) (these ligands are positively cooperative at M(2)). Verapamil, tetrahydroaminoacridine, and d-tubocurarine were also sensitive to that chimeric substitution, although verapamil and tetrahydroaminoacridine had even higher affinity for a chimera with M(2) sequence in TM7. None of these ligands shared gallamine's sensitivity to a region of the third outer loop, but studies in which obidoxime reversed the allosteric effects of gallamine and other ligands suggested that they nevertheless compete for a common site. In summary, although the present data are consistent with previous studies that have suggested that allosteric ligands bind to the outermost regions of muscarinic receptors, it appears that different allosteric ligands may derive subtype selectivity from different regions of the receptor.
Ellis
J
J
Departments of Psychiatry and Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. jxe11@psu.edu
Seidenberg
M
M
D000109:Acetylcholine / Q000378:metabolism; D000443:Alcuronium / Q000494:pharmacology*; D000494:Allosteric Regulation; D000818:Animals; D016466:CHO Cells; D002121:Calcium Channel Blockers / Q000494:pharmacology; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005707:Gallic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008024:Ligands; D019832:N-Methylscopolamine / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000187:drug effects / Q000378:metabolism
D002121:Calcium Channel Blockers; D008024:Ligands; D018733:Nicotinic Antagonists; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D011993:Recombinant Fusion Proteins; C006014:8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate; D005707:Gallic Acid; D000109:Acetylcholine; D000443:Alcuronium; D019832:N-Methylscopolamine